Attached files
| file | filename |
|---|---|
| EX-99.1 - ASSEMBLY BIOSCIENCES, INC. | v207626_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 7,
2011
|
VENTRUS
BIOSCIENCES, INC.
|
||
|
(Exact
name of registrant as specified in its charter)
|
|
Delaware
|
001-35005
|
20-8729264
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID Number)
|
|
787
7th
Avenue, 48th
Floor, New York, New York
|
10019
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code
|
(212)
554-4300
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| |_| |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|_|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|_|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR
240.14d-2(b))
|
|
|_|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01. Other Events.
On
January 7, 2011, Ventrus Biosciences, Inc. (the “Company”) issued a press
release announcing that the underwriters of the Company’s initial public
offering exercised their over-allotment option to purchase an additional 435,000
shares at $6.00 per share. A copy of this press release is
attached.
Item
9.01. Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
release dated January 7, 2011 announcing that the underwriters of the
Company’s initial public offering exercised their over-allotment option to
purchase an additional 435,000 shares at $6.00 per
share.
|
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
VENTRUS
BIOSCIENCES, INC.
|
|
|
Date: January
7, 2011
|
/s/ David J. Barrett
|
|
David
J. Barrett, Chief Financial
Officer
|
3